The Medicine Forum
Volume 21

Article 10

2020

A Case Report of Hemophagocytic Lymphohistiocytosis
Secondary to Disseminated Tuberculosis
Shuwen Lin, MD
Thomas Jefferson University, shuwen.lin@jefferson.edu

Christoher Terry
Thomas Jefferson Univeristy, christopher.terry@jefferson.edu

Follow this and additional works at: https://jdc.jefferson.edu/tmf
Part of the Internal Medicine Commons

Let us know how access to this document benefits you
Recommended Citation
Lin, MD, Shuwen and Terry, Christoher (2020) "A Case Report of Hemophagocytic Lymphohistiocytosis
Secondary to Disseminated Tuberculosis," The Medicine Forum: Vol. 21 , Article 10.
DOI: https://doi.org/10.29046/TMF.021.1.009
Available at: https://jdc.jefferson.edu/tmf/vol21/iss1/10

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in The Medicine Forum by an authorized administrator of the Jefferson Digital Commons.
For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Lin, MD and Terry: A Case Report of Hemophagocytic Lymphohistiocytosis

HEMATOLOGY & ONCOLOGY

A Case Report of Hemophagocytic
Lymphohistiocytosis Secondary to
Disseminated Tuberculosis
Shuwen Lin, MD, Christopher Terry, MD

INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) is a
life-threatening disorder characterized by excessive
activation of the immune system causing tissue damage
and organ dysfunction. Secondary HLH is more
common in adults and is usually triggered by infection,
malignancy, rheumatologic, and immunodeficiency
syndromes. We present a case of HLH secondary to
disseminated tuberculosis (TB).

CASE PRESENTATION
A 72-year-old woman with past medical history of
hypertension and type 2 diabetes presented to the
emergency department for one day history of fevers,
poor oral intake, and fatigue. She was febrile to 102.9 F
and noted to have a toxic appearance, but there were no
focal abnormalities found on exam. Initial blood work was
notable for a mild direct hyperbilirubinemia of 2.5mg/dL,
AST/ALT of 162/112 IU/L and elevated INR of 1.4. Abdominal
ultrasound showed gallbladder wall thickening. Due to
concerns for ascending cholangitis, ERCP was performed
and revealed a normal biliary system. Day 2 of hospitalization revealed new pancytopenia - her white blood cell
count was 2.7 B/L with 44% bands, hemoglobin was 10.8
g/dL, and platelet count was 39 B/L. She also had rising
hepatic function tests. Her ferritin on day 3 was
significantly elevated at 4149 IU/L, raising concerns for
HLH. On day 4, the patient became increasingly
tachypneic and tachycardic with radiographic findings of
pulmonary edema despite diuresis, as well as acute kidney
injury with decreased urine output. She was intubated for
increased work of breathing. Due to a high suspicion of
HLH with the probability of HLH greater than 99%
calculated by the HScore, methylprednisolone 120mg
daily in split doses was initiated. Etoposide was not started
due to her multiorgan dysfunction. On day 5, her liver and
kidney failure worsened, and her ferritin and triglycerides
continued to rise. She also developed hypofibrinogenemia concerning for DIC. On day 6, methylprednisolone was changed to dexamethasone 8mg Q6 and
anakinra 100mg Q12 was added, but this was discontinued
on day 7 when her liver biopsy showed many caseating
and non-caseating granulomas with AFB stain positive for
acid-fast bacilli. Sputum AFB stains were also obtained
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positive for acid fast bacilli. Sputum PCR showed
Mycobacterium tuberculosis (TB) leading to the
presumptive diagnosis of HLH secondary to disseminated
TB. Due to the patient’s acute liver failure, a modified
regimen of TB treatment was initiated including rifampin,
ethambutol, levofloxacin, and amikacin. Despite TB
treatment, immunosuppression for HLH, and supportive
measures, the patient continued to deteriorate and
expired on day 10.

DISCUSSION
Although HLH secondary to TB (TB-HLH) has previously
been reported in the medical literature, it remains a rare
entity.1 Most patients with TB-HLH had short symptom
duration and rapid progression leading to multi-organ
dysfunction and ultimately, death.
The first HLH treatment protocol was published in 1994
(HLH-94) and has been widely used in clinical practice.
HLH -94 includes an anti - inf lammator y agent ,
dexamethasone, and a pro-apoptotic agent, etoposide.
This regimen has been shown to improve survival but was
primarily based on data in the pediatric setting, many with
primary HLH.2 Furthermore, etoposide was not determined
to be a safe option due to her multi-organ dysfunction.
Instead, anakinra, an IL-1 receptor antagonist was used in
combination of dexamethasone. Anakinra as an immunomodulator has also been shown to be effective in the
treatment of severe HLH in the critical care setting. 3-4
Additionally, secondary HLH is often triggered by an acute
infection or other condition (eg, rheumatologic condition)
and treatment should be to address the underlying cause
of immune activation. Although there is no consensus of
standard treatment for TB-HLH, a systematic review of
the international literature demonstrates that a delay or
absence of antitubercular therapy (ATT) were associated
with decreased survival.5 On the contrary, the combination
of antitubercular therapy (ATT) with immunotherapy has
been found to significantly reduce mortality.1 Our patient
was initiated on a modified regimen of ATT as soon as the
diagnosis of disseminated TB was made, but she still
passed several days later. This case highlights the need for
ongoing investigation for early detection and management
of secondary HLH in the adult setting.
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